CN100488981C - 含有蛋白酶激活序列的气单胞菌溶素原及其应用 - Google Patents

含有蛋白酶激活序列的气单胞菌溶素原及其应用 Download PDF

Info

Publication number
CN100488981C
CN100488981C CNB028166221A CN02816622A CN100488981C CN 100488981 C CN100488981 C CN 100488981C CN B028166221 A CNB028166221 A CN B028166221A CN 02816622 A CN02816622 A CN 02816622A CN 100488981 C CN100488981 C CN 100488981C
Authority
CN
China
Prior art keywords
prostate
peptide
psa
cells
aerolysin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB028166221A
Other languages
English (en)
Chinese (zh)
Other versions
CN1636017A (zh
Inventor
萨穆尔·R·登米德
约翰·T·伊萨克斯
詹姆士·托马斯·巴克利
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
OF VCTORIA INNOVATION AND DEVELOPMENT CORP, University of
Johns Hopkins University
Original Assignee
OF VCTORIA INNOVATION AND DEVELOPMENT CORP, University of
Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by OF VCTORIA INNOVATION AND DEVELOPMENT CORP, University of, Johns Hopkins University filed Critical OF VCTORIA INNOVATION AND DEVELOPMENT CORP, University of
Publication of CN1636017A publication Critical patent/CN1636017A/zh
Application granted granted Critical
Publication of CN100488981C publication Critical patent/CN100488981C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
    • A61K39/001194—Prostate specific antigen [PSA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
    • A61K39/001195—Prostate specific membrane antigen [PSMA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/32—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bacillus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/32—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bacillus (G)
    • C07K14/325—Bacillus thuringiensis crystal peptides, i.e. delta-endotoxins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CNB028166221A 2001-08-24 2002-08-23 含有蛋白酶激活序列的气单胞菌溶素原及其应用 Expired - Fee Related CN100488981C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31461301P 2001-08-24 2001-08-24
US60/314,613 2001-08-24

Publications (2)

Publication Number Publication Date
CN1636017A CN1636017A (zh) 2005-07-06
CN100488981C true CN100488981C (zh) 2009-05-20

Family

ID=23220660

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB028166221A Expired - Fee Related CN100488981C (zh) 2001-08-24 2002-08-23 含有蛋白酶激活序列的气单胞菌溶素原及其应用

Country Status (11)

Country Link
US (3) US7282476B2 (enExample)
EP (2) EP2518142B1 (enExample)
JP (1) JP4319908B2 (enExample)
CN (1) CN100488981C (enExample)
AU (1) AU2002331720B2 (enExample)
CA (1) CA2457903C (enExample)
DK (1) DK1567641T3 (enExample)
ES (2) ES2542888T3 (enExample)
PT (1) PT1567641E (enExample)
WO (1) WO2003018611A2 (enExample)
ZA (1) ZA200402319B (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004021861A2 (en) * 2002-09-03 2004-03-18 Vit Lauermann Targeted release
WO2004078097A2 (en) * 2003-03-03 2004-09-16 University Of Victoria Innovation And Development Corporation Modified aerolysin linked to a lung cancer binding agent and methods of use for treating lung cancer
PL1694845T3 (pl) 2003-11-28 2019-01-31 National Research Council Of Canada Przeciwciała przeciwko rakowi i ich zastosowania
EP1891093B1 (en) 2005-06-14 2011-03-23 Protox Therapeutics Incorporated Method of treating or preventing benign prostatic hyperplasia using modified pore-forming proteins
CN100443503C (zh) * 2005-07-18 2008-12-17 四川大学华西医院 人源化ctla-4单链抗体与人穿孔素通道形成肽p34的重组免疫毒素
US20090016988A1 (en) * 2005-11-21 2009-01-15 Buckley J Thomas Modified Pore-Forming Protein Toxins and Use Thereof
US8993295B2 (en) 2006-07-20 2015-03-31 The General Hospital Corporation Methods, compositions, and kits for the selective activation of protoxins through combinatorial targeting
CA2696627C (en) 2007-08-17 2016-09-27 Purdue Research Foundation Psma binding ligand-linker conjugates and methods for using
WO2010069060A1 (en) * 2008-12-15 2010-06-24 Protox Therapeutics Inc. Method for treating prostatitis utilizing modified pore-forming protein proaerolysin
ES2625470T3 (es) 2009-11-09 2017-07-19 Alexion Pharmaceuticals, Inc.. Reactivos y métodos para detectar glóbulos blancos asociados a HPN de tipo II y su identificación como factores de riesgo para trastornos trombóticos
US9951324B2 (en) 2010-02-25 2018-04-24 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
EP2629788A4 (en) * 2010-10-22 2014-03-19 Protox Therapeutics Corp USE OF HUMAN SERUM ALBUMIN TO REDUCE THE ANTIGENICITY OF THERAPEUTIC PROTEINS
KR102354613B1 (ko) 2012-11-15 2022-01-21 엔도사이트, 인코포레이티드 Psma 발현 세포에 의해 야기되는 질병을 치료하기 위한 컨쥬게이트
US9789209B2 (en) 2013-03-14 2017-10-17 The Regents Of The University Of California, Berke Activatable membrane-interacting peptides and methods of use
HUE066137T2 (hu) 2013-10-18 2024-07-28 Novartis Ag A prosztata-specifikus membrán antigén (PSMA) jelzett inhibitorai, alkalmazásuk képalkotásban és gyógyszerkészítmények prosztatarák kezelésére
US10464970B2 (en) 2013-10-23 2019-11-05 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Compounds that bind to human immunodeficiency virus rev response element
JP6464166B2 (ja) 2013-11-14 2019-02-06 エンドサイト・インコーポレイテッドＥｎｄｏｃｙｔｅ， Ｉｎｃ． 陽電子放出断層撮影用の化合物
US10188759B2 (en) 2015-01-07 2019-01-29 Endocyte, Inc. Conjugates for imaging
US10596226B2 (en) * 2015-01-16 2020-03-24 The Johns Hopkins University Albumin-proaerolysin prodrugs
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
EP3407906A4 (en) * 2016-01-27 2019-10-09 Sophiris Bio, Inc. METHOD FOR THE TARGETED INTRAPROSTATIC ADMINISTRATION OF PRX302 FOR THE TREATMENT OF PROSTATE CANCER
CN109790206A (zh) * 2016-09-22 2019-05-21 分子组合公司 重组结合蛋白及其用途
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
WO2019073299A1 (en) 2017-10-10 2019-04-18 Medicenna Therapeutics, Inc. IL-4 FUSION FORMULATIONS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM (CNS) TUMORS
CA3097381A1 (en) 2018-04-17 2019-10-24 Endocyte, Inc. Methods of treating cancer
CN120097930A (zh) 2019-05-20 2025-06-06 因多塞特股份有限公司 制备psma缀合物的方法
WO2021156890A2 (en) * 2020-02-03 2021-08-12 Premas Biotech Private Limited Recombinant expression platform, constructs and methods for expression of difficult to express proteins (dte-ps)
US11845779B2 (en) * 2020-10-28 2023-12-19 Ecole Polytechnique Federale De Lausanne (Epfl) Mutant aerolysin and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5777078A (en) * 1993-04-28 1998-07-07 Worcester Foundation For Experimental Biology Triggered pore-forming agents
US5817771A (en) * 1993-04-28 1998-10-06 Worcester Foundation For Experimental Biology Cell-targeted lytic pore-forming agents
WO2000001419A1 (en) * 1998-07-06 2000-01-13 Jcrt Radiation Oncology Support Services, Inc. Drug complex for treatment of metastatic prostate cancer

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US5264550A (en) 1985-04-15 1993-11-23 Scios Nova Inc. Human anti-inflammatory phospholipase inhibitor protein
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
US5858358A (en) * 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
US5529774A (en) 1991-08-13 1996-06-25 The Regents Of The University Of California In vivo transfer of the HSV-TK gene implanted retroviral producer cells
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US6057133A (en) 1992-11-24 2000-05-02 G. D. Searle Multivariant human IL-3 fusion proteins and their recombinant production
US5677274A (en) * 1993-02-12 1997-10-14 The Government Of The United States As Represented By The Secretary Of The Department Of Health And Human Services Anthrax toxin fusion proteins and related methods
DK0700430T3 (da) 1993-06-04 2005-08-15 Us Navy Fremgangsmåder til selektivt af stimulere proliferation af T-celler
US5691188A (en) 1994-02-14 1997-11-25 American Cyanamid Company Transformed yeast cells expressing heterologous G-protein coupled receptor
WO1995026204A1 (en) 1994-03-25 1995-10-05 Isis Pharmaceuticals, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
WO1995027512A2 (en) 1994-04-11 1995-10-19 Baylor College Of Medicine Compositions and methods for gene therapy to treat disease
US6143864A (en) * 1994-06-28 2000-11-07 Merck & Co., Inc. Peptides
US5599686A (en) * 1994-06-28 1997-02-04 Merck & Co., Inc. Peptides
US5866679A (en) * 1994-06-28 1999-02-02 Merck & Co., Inc. Peptides
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
EP0772619B2 (en) 1994-07-15 2010-12-08 The University of Iowa Research Foundation Immunomodulatory oligonucleotides
US6190657B1 (en) * 1995-06-07 2001-02-20 Yale University Vectors for the diagnosis and treatment of solid tumors including melanoma
US6066319A (en) 1996-04-30 2000-05-23 President And Fellows Of Harvard College Drug delivery using terminal complement components
US6072041A (en) 1996-06-03 2000-06-06 Case Western Reserve University Fusion proteins for protein delivery
US5856462A (en) 1996-09-10 1999-01-05 Hybridon Incorporated Oligonucleotides having modified CpG dinucleosides
US5998362A (en) * 1996-09-12 1999-12-07 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
US5798218A (en) * 1996-09-24 1998-08-25 University Of British Columbia Innovation And Development Corporation Compositions and methods for the specific detection of thy-1 antigen
US5948750A (en) * 1996-10-30 1999-09-07 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
AU716564B2 (en) 1996-11-06 2000-03-02 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Protease-activatable pseudomonas exotoxin A-like proproteins
AU738513B2 (en) 1997-02-28 2001-09-20 University Of Iowa Research Foundation, The Use of nucleic acids containing unmethylated CpG dinucleotide in the treatment of LPS-associated disorders
EP1005368B1 (en) 1997-03-10 2009-09-02 Ottawa Hospital Research Institute Use of nucleic acids containing unmethylated CpG dinucleotide in combination with alum as adjuvants
CA2283639A1 (en) 1997-03-14 1998-09-24 The Children's Hospital Of Philadelphia Methods and compositions for use in gene therapy for treatment of hemophilia
US6545131B1 (en) * 1997-05-19 2003-04-08 The Johns Hopkins University Tissue specific prodrug
US6504014B1 (en) * 1997-05-19 2003-01-07 The John Hopkins University Tissue specific prodrug
WO1998052966A1 (en) 1997-05-19 1998-11-26 The Johns Hopkins University School Of Medecine Tissue specific prodrug
DE69838294T2 (de) 1997-05-20 2009-08-13 Ottawa Health Research Institute, Ottawa Verfahren zur Herstellung von Nukleinsäurekonstrukten
WO1999002175A1 (en) 1997-07-10 1999-01-21 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
ES2163293T5 (es) * 1997-08-15 2006-01-16 Cephalon, Inc. Combinacion de un inhibidor de tirosina quinasas y castracion quimica para tratar el cancer de prostata.
US6391305B1 (en) 1997-09-10 2002-05-21 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
GB9721901D0 (en) 1997-10-16 1997-12-17 Univ Manchester Particles
AU2326199A (en) * 1998-01-20 1999-08-02 Johns Hopkins University, The Detection of gpi anchored proteins
US6180356B1 (en) * 1998-03-06 2001-01-30 The Research Foundation Of State University Of Ny Membrane pore inhibiting agents for treating infection
US6221349B1 (en) 1998-10-20 2001-04-24 Avigen, Inc. Adeno-associated vectors for expression of factor VIII by target cells
CA2366794A1 (en) * 1999-04-09 2000-10-19 The Johns Hopkins University Channel forming toxins as antiviral agents
KR20020027311A (ko) 1999-05-07 2002-04-13 제넨테크, 인크. Ｂ 세포 표면 마커에 결합하는 길항물질을 이용한자가면역 질환의 치료
EP1052287A3 (en) 1999-05-10 2003-07-09 Transgene S.A. Complex for transferring an anionic substance of interest into a cell
EP1052288A1 (en) 1999-05-10 2000-11-15 Transgene S.A. Complex for transferring an anionic substance of interest into a cell
AU7627200A (en) 1999-07-29 2001-02-19 Johns Hopkins University, The Activation of peptide prodrugs by hk2
US7053042B1 (en) * 1999-07-29 2006-05-30 Samuel Denmeade Activation of peptide prodrugs by hK2
EP1224312A1 (en) 1999-10-12 2002-07-24 The University of North Carolina at Chapel Hill Adeno-associated virus vectors encoding factor viii and methods of using the same
JP2003513046A (ja) * 1999-11-01 2003-04-08 アルコン，インコーポレイテッド フルオロキノロン抗生薬およびキサンタンガムを含有する薬学的組成物
EP1282642B1 (en) 2000-05-09 2006-09-06 Greenville Hospital System Therapeutic pore-forming peptides
US20020041880A1 (en) * 2000-07-05 2002-04-11 Defeo-Jones Deborah Method of treating cancer
FI116467B (fi) 2000-09-29 2005-11-30 Licentia Oy Uudet peptidiligandit
AU2002223316A1 (en) * 2000-11-07 2002-05-21 University Of Victoria Innovation And Development Corporation Detection of proteases and screening for protease inhibitors
AU2002239403A1 (en) 2000-12-01 2002-06-11 The Johns Hopkins University Tissue specific prodrugs
US7456146B2 (en) * 2001-05-09 2008-11-25 Ghc Research Development Corporation Lytic peptide prodrugs

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5777078A (en) * 1993-04-28 1998-07-07 Worcester Foundation For Experimental Biology Triggered pore-forming agents
US5817771A (en) * 1993-04-28 1998-10-06 Worcester Foundation For Experimental Biology Cell-targeted lytic pore-forming agents
WO2000001419A1 (en) * 1998-07-06 2000-01-13 Jcrt Radiation Oncology Support Services, Inc. Drug complex for treatment of metastatic prostate cancer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
The pore-forming toxin proaerolysin is activated by furin. Laurence Abrami等.The Journal of Biological Chemistry,Vol.273 No.49. 1998 *

Also Published As

Publication number Publication date
US7282476B2 (en) 2007-10-16
CA2457903A1 (en) 2003-03-06
US20080089869A1 (en) 2008-04-17
WO2003018611A2 (en) 2003-03-06
CN1636017A (zh) 2005-07-06
US7838266B2 (en) 2010-11-23
WO2003018611A3 (en) 2005-06-30
HK1178563A1 (en) 2013-09-13
US7745395B2 (en) 2010-06-29
ES2542888T3 (es) 2015-08-12
EP1567641A4 (en) 2005-12-28
JP4319908B2 (ja) 2009-08-26
JP2005520490A (ja) 2005-07-14
US20040235095A1 (en) 2004-11-25
EP1567641A2 (en) 2005-08-31
CA2457903C (en) 2018-04-17
ES2388170T3 (es) 2012-10-09
PT1567641E (pt) 2012-08-21
ZA200402319B (en) 2005-08-30
EP1567641B1 (en) 2012-05-23
EP2518142B1 (en) 2015-07-15
DK1567641T3 (da) 2012-08-27
AU2002331720B2 (en) 2007-10-11
EP2518142A1 (en) 2012-10-31
US20100234300A1 (en) 2010-09-16

Similar Documents

Publication Publication Date Title
CN100488981C (zh) 含有蛋白酶激活序列的气单胞菌溶素原及其应用
AU2002331720A1 (en) Proaerolysin containing protease activation sequences and methods of use for treatment of prostate cancer
US20200283498A1 (en) T cell receptor fusions and conjugates and methods of use thereof
EP1315742A1 (en) Amino acid substitution mutants of interleukin 13
WO2007140618A1 (en) Modified protein toxins targeting cytokine -receptor bearing cells and use thereof for treating disease
US20090016988A1 (en) Modified Pore-Forming Protein Toxins and Use Thereof
US10654900B2 (en) Method for treating prostatitis utilizing the pore-forming protein proaerolysin PRX302
US20090226942A1 (en) Modified aerolysin and methods of use for treating lung cancer
HK1178563B (en) Proaerolysin containing protease activation sequences and methods of use for treatment of prostate cancer
US20180148480A1 (en) Synthetic enhancement of the t-cell armamentarium as an anti-cancer therapy
WO2024214083A1 (en) Use of immunomodulation methods in combination with cytokine fusions for disease treatment
AU2001288405A1 (en) Amino acid substitution mutants of interleukin 13

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20090520

Termination date: 20200823

CF01 Termination of patent right due to non-payment of annual fee